Search

Your search keyword '"Andea, Aleodor A."' showing total 368 results
Start Over Author "Andea, Aleodor A."
368 results on '"Andea, Aleodor A."'

2. Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee

Author

Members, AUC Committee, Fung, Maxwell A, Vidal, Claudia I, Armbrecht, Eric A, Andea, Aleodor A, Cassarino, David S, Comfere, Nneka I, Emanuel, Patrick O, Ferringer, Tammie, Hristov, Alexandra C, Kim, Jinah, Lauer, Scott R, Linos, Konstantinos, Missall, Tricia A, Motaparthi, Kiran, Novoa, Roberto A, Patel, Rajiv, Shalin, Sara C, Sundram, Uma, Panel, Rating, Calame, Antoanella, Bennett, Daniel D, Duncan, Lyn M, Elston, Dirk M, Hosler, Gregory A, Hurley, Yadira M, Lazar, Alexander J, Lowe, Lori, Messina, Jane, Myles, Jonathan, Plaza, Jose A, Prieto, Victor G, Reddy, Vijaya, Schaffer, András, and Subtil, Antonio

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Dermatology, Evidence-Based Medicine, Humans, Pathology, Clinical, Skin Diseases, Societies, Medical, United States, ancillary studies, angiosarcoma, appropriate use criteria, choosing wisely, cMYC, dermatitis, dermatology, dermatopathology, dermatophytosis, diagnosis, evidence-based medicine, expert rating, Gomori methenamine silver, Grocott-Gomori, immunohistochemistry, in situ hybridization, kappa, lambda, lymphoma, onychomycosis, pathology, periodic acid-Schiff, RAND, UCLA appropriateness method, TERT promoter, tinea, AUC Committee Members, Rating Panel, Grocott-Gömöri, Gömöri methenamine silver, RAND/UCLA appropriateness method, Clinical Sciences, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundAppropriate use criteria (AUC) provide patient-centered physician guidance in test selection. An initial set of AUC was reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience. The objective of this study was to update and expand AUC for selected tests.MethodsRAND/UCLA (RAND Corporation [Santa Monica, CA]/University of California Los Angeles) methodology used includes the following: (a) literature review; (b) review of previously rated tests and previously employed clinical scenarios; (c) selection of previously rated tests for new ratings; (d) development of new clinical scenarios; (e) selection of additional tests; (f) three rating rounds with feedback and group discussion after rounds 1 and 2.ResultsFor 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (comparative genomic hybridization, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, telomerase reverse transcriptase promoter), vascular disorders (MYC), and inflammatory dermatoses (periodic acid-Schiff, Gömöri methenamine silver), consensus by panel raters was reached in 172 of 220 (78%) scenarios, with 103 of 148 (70%) rated "usually appropriate" or "rarely appropriate" and 45 of 148 (30%), "appropriateness uncertain."LimitationsThe study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded.ConclusionsAUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve healthcare delivery.

Published
2022

9. Vulvar syringoma

Author

Garib, George, Lullo, Jenna Janiga, and Andea, Aleodor A.

Subjects
Teenage girls, Health, The University of Alabama at Birmingham
Abstract

To the Editor: Syringomas are common benign tumors of the eccrine sweat glands that usually manifest clinically as multiple flesh-colored papules. They are most commonly seen on the face, neck, [...]

Published
2023

19. Genomic Applications in Melanoma

Author

Prieto-Granada, Carlos N., Van Arnam, John, Shah, Kabeer K., Andea, Aleodor A., Lazar, Alexander J., Netto, George Jabboure, editor, and Kaul, Karen L., editor

Published
2019
Full Text
View/download PDF

21. Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology

Author

Vidal, Claudia I., Armbrect, Eric A., Andea, Aleodor A., Bohlke, Angela K., Comfere, Nneka I., Hughes, Sarah R., Kim, Jinah, Kozel, Jessica A., Lee, Jason B., Linos, Konstantinos, Litzner, Brandon R., Missall, Tricia A., Novoa, Roberto A., Sundram, Uma, Swick, Brian L., Hurley, M. Yadira, Alam, Murad, Argenyi, Zsolt, Duncan, Lyn M., Elston, Dirk M., Emanuel, Patrick O., Ferringer, Tammie, Fung, Maxwell A., Hosler, Gregory A., Lazar, Alexander J., Lowe, Lori, Plaza, Jose A., Prieto, Victor G., Robinson, June K., Schaffer, Andras, Subtil, Antonio, and Wang, Wei-Lien

Published
2019
Full Text
View/download PDF

31. Genomic Applications in Melanoma

Author

Prieto-Granada, Carlos N., primary, Van Arnam, John, additional, Shah, Kabeer K., additional, Andea, Aleodor A., additional, and Lazar, Alexander J., additional

Published
2018
Full Text
View/download PDF

32. Cutaneous malakoplakia arising on the ankle of a patient with pyoderma gangrenosum.

Author

Whittington, Carli P., Saleh, Jasmine S., Schadler, Eric, Bitar, Carole, Wang, Frank, and Andea, Aleodor A.

Subjects
PYODERMA gangrenosum, SYMPTOMS, BACTERIAL diseases, IMMUNOSTAINING, IMMUNOSUPPRESSIVE agents, ANKLE
Abstract

Malakoplakia is a rare chronic inflammatory condition that most commonly involves the urogenital tract. Cutaneous malakoplakia is extremely rare and many patients diagnosed with skin involvement are immunosuppressed. While the clinical presentation of cutaneous malakoplakia is variable, the histopathologic features are quite distinct and include sheets of closely packed dermal histiocytes with foamy‐appearing cytoplasm and Michaelis–Gutmann bodies that are positive with certain immunohistochemical stains. While the exact pathogenesis of malakoplakia is unknown, it has been associated with certain bacterial infections. Treatment generally involves a combination of surgery and antimicrobial agents and/or modulation of immunosuppressant therapy if appropriate. Herein, the authors report a unique case of cutaneous malakoplakia arising in a patient on chronic immunosuppressive therapy for the management of pyoderma gangrenosum. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Melanoma developing in a nevoid melanocytoma with myxoid changes: a case report

Author

Kao, Andrew S, St Claire, Kayla, Bedford, Lisa M, Mehregan, Darius R, Andea, Aleodor A, and Kouba, David

Subjects
stomatognathic diseases, Case Report
Abstract

Nevoid and myxoid melanoma are rare variants of melanoma; association of the two is a unique finding. Nevoid melanoma is characterized by morphologic resemblance to a nevus, whereas myxoid melanoma demonstrates a basophilic mucinous matrix. We present an atypical case of a melanoma progressing from a nevoid melanocytoma with myxoid changes. A 78-year-old female presented with a pigmented growth on her right thigh. Biopsy demonstrated a biphenotypic melanocytic proliferation composed of a nodule showing epithelioid melanocytes with enlarged nuclei, prominent nucleoli, lack of maturation, and abundant amphophilic cytoplasm with a rare mitotic figure. These findings were suggestive of melanoma along with a nevoid dermal component and myxoid stroma. FISH testing revealed a homozygous loss of 9p21 in the atypical component. SNP-microarray from the nevoid component demonstrated three abnormalities including a gain of whole chromosome 8, as well as loss of a copy of nearly an entire chromosome 9 and 16q most consistent with a melanocytoma.

Published
2022

44. Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee.

Author

AUC Committee Members, AUC Committee Members, Fung, Maxwell A, Vidal, Claudia I, Armbrecht, Eric A, Andea, Aleodor A, Cassarino, David S, Comfere, Nneka I, Emanuel, Patrick O, Ferringer, Tammie, Hristov, Alexandra C, Kim, Jinah, Lauer, Scott R, Linos, Konstantinos, Missall, Tricia A, Motaparthi, Kiran, Novoa, Roberto A, Patel, Rajiv, Shalin, Sara C, Sundram, Uma, Rating Panel, Calame, Antoanella, Bennett, Daniel D, Duncan, Lyn M, Elston, Dirk M, Hosler, Gregory A, Hurley, Yadira M, Lazar, Alexander J, Lowe, Lori, Messina, Jane, Myles, Jonathan, Plaza, Jose A, Prieto, Victor G, Reddy, Vijaya, Schaffer, András, Subtil, Antonio, AUC Committee Members, AUC Committee Members, Fung, Maxwell A, Vidal, Claudia I, Armbrecht, Eric A, Andea, Aleodor A, Cassarino, David S, Comfere, Nneka I, Emanuel, Patrick O, Ferringer, Tammie, Hristov, Alexandra C, Kim, Jinah, Lauer, Scott R, Linos, Konstantinos, Missall, Tricia A, Motaparthi, Kiran, Novoa, Roberto A, Patel, Rajiv, Shalin, Sara C, Sundram, Uma, Rating Panel, Calame, Antoanella, Bennett, Daniel D, Duncan, Lyn M, Elston, Dirk M, Hosler, Gregory A, Hurley, Yadira M, Lazar, Alexander J, Lowe, Lori, Messina, Jane, Myles, Jonathan, Plaza, Jose A, Prieto, Victor G, Reddy, Vijaya, Schaffer, András, and Subtil, Antonio

Abstract

BackgroundAppropriate use criteria (AUC) provide patient-centered physician guidance in test selection. An initial set of AUC was reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience. The objective of this study was to update and expand AUC for selected tests.MethodsRAND/UCLA (RAND Corporation [Santa Monica, CA]/University of California Los Angeles) methodology used includes the following: (a) literature review; (b) review of previously rated tests and previously employed clinical scenarios; (c) selection of previously rated tests for new ratings; (d) development of new clinical scenarios; (e) selection of additional tests; (f) three rating rounds with feedback and group discussion after rounds 1 and 2.ResultsFor 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (comparative genomic hybridization, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, telomerase reverse transcriptase promoter), vascular disorders (MYC), and inflammatory dermatoses (periodic acid-Schiff, Gömöri methenamine silver), consensus by panel raters was reached in 172 of 220 (78%) scenarios, with 103 of 148 (70%) rated "usually appropriate" or "rarely appropriate" and 45 of 148 (30%), "appropriateness uncertain."LimitationsThe study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded.ConclusionsAUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve healthcare delivery.

Published
2022

46. Combined utility of p16 and BRAF V600E in the evaluation of spitzoid tumors: Superiority to PRAME and correlation with FISH.

Author

McAfee, John L., Scarborough, Richard, Jia, Xuefei Sophia, Azzato, Elizabeth M., Astbury, Caroline, Ronen, Shira, Andea, Aleodor A., Billings, Steven D., and Ko, Jennifer S.

Subjects
P16 gene, BRAF genes, FLUORESCENCE in situ hybridization, DYSPLASTIC nevus syndrome, FISHER exact test
Abstract

Background: Spitzoid melanocytic neoplasms are diagnostically challenging; criteria for malignancy continue to evolve. The ability to predict chromosomal abnormalities with immunohistochemistry (IHC) could help select cases requiring chromosomal evaluation. Methods: Fluorescence in situ hybridization (FISH)‐tested spitzoid neoplasms at our institution (2013–2021) were reviewed. p16, BRAF V600E, and preferentially expressed antigen in melanoma (PRAME) IHC results were correlated with FISH. Results: A total of 174 cases (1.9F:1M, median age 28 years; range, 5 months–74 years) were included; final diagnoses: Spitz nevus (11%), atypical Spitz tumor (47%), spitzoid dysplastic nevus (9%), and spitzoid melanoma (32%). Sixty (34%) were FISH positive, most commonly with absolute 6p25 gain (RREB1 > 2). Dermal mitotic count was the only clinicopathologic predictor of FISH. Among IHC‐stained cases, p16 was lost in 55 of 134 cases (41%); loss correlated with FISH positive (p < 0.001, Fisher exact test). BRAF V600E (14/88, 16%) and PRAME (15/56, 27%) expression did not correlate with FISH alone (p = 0.242 and p = 0.359, respectively, Fisher exact test). When examined together, however, p16‐retained/BRAF V600E‐negative lesions had low FISH‐positive rates (5/37, 14%; 4/37, 11% not counting isolated MYB loss); all other marker combinations had high rates (56%–75% of cases; p < 0.001). Conclusions: p16/BRAF V600E IHC predicts FISH results. "Low‐risk" lesions (p16+/BRAF V600E−) uncommonly have meaningful FISH abnormalities (11%). PRAME may have limited utility in this setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results